For readers searching "best peptides for sleep," the short answer most experienced users describe in community sources is this: sleep peptides aren't interchangeable, and the right pick depends on what's broken. DSIP targets sleep architecture (the deep stages). Selank targets anxiety-driven onset difficulty. MK-677 amplifies the natural growth-hormone pulse that drives slow-wave sleep. Ipamorelin engages the same GH pathway with more selectivity. Most community-described stacks layer two peptides whose mechanisms don't overlap, rather than picking a single "best" one.
Research-context information only. Peptides discussed below are research compounds. Protocols, doses, and reactions reported come from published research and self-reported community sources. This article reports what has been documented, not what should be done. Consult a licensed physician for personal medical decisions.
Evidence at a glance
Peptides covered below, sorted by clinical evidence strength. Each peptide also carries a parallel community-evidence grade reflecting real-world adoption. How we grade evidence.
Reduces bedtime anxiety in small Russian RCTs; not a direct hypnotic.
This guide ranks the four peptides community sources most commonly describe for sleep, in the order trial-evidence strength and real-world adoption tend to rank them. Each entry explains what trial data and community usage describe in a sleep context, who typically chooses it, and what self-reported community outcomes look like. Dosing, injection timing, and bloodwork details live in the linked deep-dive guides.
The Rankings
Bac Water Made for Peptides
Don't risk a $300 peptide on generic bac water.
Most cloudy reconstitutions trace back to one thing — and it isn't the peptide. Sterile, non-pyrogenic, 0.9% benzyl alcohol — formulated for peptide reconstitution, not repackaged from generic stock.
✓ 0.9% benzyl alcohol✓ Made for peptides✓ 30 mL multi-dose
30ml from $18.75 · Ships fast · Code thepeptidecatalog
1. DSIP (Delta Sleep-Inducing Peptide) — the architecture pick
Best for: users with poor deep sleep, fragmented or non-restorative sleep despite adequate time in bed, or those cycling off conventional sedatives.
DSIP is a nine-amino-acid neuropeptide first isolated from rabbit brain dialysates in 1977. Researchers found that cerebrospinal fluid from sleeping rabbits, when transferred to awake rabbits, induced slow-wave delta EEG patterns — hence the name. DSIP is present in human blood and cerebrospinal fluid, with concentrations that fluctuate in a circadian pattern, peaking during evening hours.
The mechanism remains incompletely understood. DSIP's specific receptor has never been definitively identified, and the gene encoding it remains undiscovered. What published research describes is that DSIP interacts with multiple neurotransmitter systems rather than a single receptor pathway: GABAergic transmission (the same inhibitory system targeted by benzodiazepines), glutamatergic signaling, and serotonergic pathways involved in sleep-wake transitions. This multi-system engagement is what published research describes as explaining why DSIP promotes natural-appearing sleep architecture rather than the uniform sedation produced by single-target drugs. Beyond sleep, DSIP reportedly reduces ACTH and cortisol output under stress conditions — directly relevant since elevated evening cortisol is one of the most common physiological drivers of poor sleep.
Clinical data on DSIP in human insomnia is mixed but notable. A double-blind study in chronic insomniacs reported higher sleep efficiency and shorter sleep latency with DSIP compared to placebo, though authors described the effects as modest with short-term use. More promising results came from studies using repeated administrations, which described a cumulative buildup effect: sleep structure normalized after four consecutive doses, with longer sleep duration and fewer interruptions. One case study described DSIP advancing the main sleep phase by five hours in a patient with chronic delayed sleep-phase disorder.
Community reports on DSIP cluster around three themes: improved sleep within the first 1-3 doses (the most consistently described early signal), cumulative deepening of the effect over consecutive nights, and the practical caveat — DSIP is more fragile than most research peptides, requiring refrigerated storage after reconstitution and use within 3-4 weeks. Trial protocols and community sources commonly describe 100-300 mcg subcutaneously, 30-60 minutes before bed, cycled 10 days on / 10-20 days off.
2. MK-677 (Ibutamoren) — the oral GH-mediated pick
Best for: users with age-related sleep deterioration (especially adults 40+), users combining sleep goals with body composition or recovery, or those who don't want to inject.
MK-677 is the only oral compound on this list. It activates the GHS-R1a receptor (the ghrelin receptor) in the hypothalamus and pituitary, stimulating growth hormone secretion in a pulsatile pattern that mimics natural physiology. Published research describes endogenous ghrelin levels rising in the evening and peaking during the first half of the night — coinciding with slow-wave-sleep-dominant cycles. MK-677 amplifies this natural pattern.
The sleep data is the strongest single-trial dataset of any compound on this list. A double-blind placebo-controlled crossover study (Copinschi et al.) administered 25 mg MK-677 at bedtime to healthy young men for seven days. Stage IV sleep duration reportedly increased approximately 50%, REM sleep increased more than 20%, and deviations from normal sleep patterns dropped from 42% to 8%. In older adults (ages 65-71), 25 mg reportedly produced a nearly 50% increase in REM sleep with decreased REM latency. The age-dependent response is notable — older adults have substantially lower baseline GH and less slow-wave sleep, so the relative improvement may be more pronounced in this population.
The mechanism connects to a documented bidirectional feedback loop: published research describes approximately 70% of GH pulses during sleep coinciding with slow-wave sleep. By amplifying GH secretion, MK-677 reinforces this cycle.
Community reports on MK-677 cluster around three themes: noticeable sleep deepening within the first week (consistent with the trial timeline), increased appetite that's reported as the most consistent side effect at 25 mg, and metabolic shifts — trial data and community sources both describe MK-677 raising fasting glucose and insulin even in metabolically healthy subjects. Community sources commonly describe starting at 10-12.5 mg to minimize appetite and glucose effects while still producing meaningful GH elevation. Trial protocols describe 10-25 mg orally at bedtime; community sources commonly describe 8-12 week protocols with bloodwork monitoring at baseline and midpoint.
Best for: users whose insomnia is driven by racing thoughts, rumination, or generalized anxiety rather than a primary sleep-architecture deficit.
Selank is a synthetic heptapeptide derived from tuftsin, a naturally occurring immunomodulatory tetrapeptide cleaved from the Fc region of IgG. The Pro-Gly-Pro extension was engineered to confer resistance to aminopeptidase degradation, extending selank's biological half-life from minutes to hours.
The anxiolytic mechanism is dual. Published research describes selank inhibiting enkephalin-degrading enzymes in a dose-dependent manner, which stabilizes endogenous opioid peptides regulating mood and pain perception. It also modulates GABAergic neurotransmission — a clinical study reported selank altering the expression of 45 genes involved in GABA signaling within one hour of administration, with patterns similar to GABA itself. The dose-response curve for anxiolysis appears to plateau in the 250-500 mcg intranasal range. In human clinical trials, selank reportedly demonstrated anxiolytic efficacy comparable to the benzodiazepine medazepam in patients with generalized anxiety disorder, but with antiasthenic and mild psychostimulant effects rather than sedation.
Distinguishing anxiety-driven insomnia from primary insomnia matters for peptide selection. Trial data describe primary insomnia as involving a direct deficit in sleep architecture, while anxiety-driven insomnia features intact sleep machinery overridden by hyperactive arousal circuits — the HPA axis stays activated, cortisol remains elevated, and sympathetic tone stays high. Selank targets the anxiety circuitry rather than the sleep architecture itself.
Community reports on selank cluster around three themes: noticeable anxiety reduction within days of starting (commonly described as the earliest signal), gradual improvement in sleep onset over 1-2 weeks (downstream of the anxiolytic effect rather than directly induced), and the practical advantage of the intranasal route — rapid CNS absorption with no injection. Trial protocols and community sources commonly describe 250-500 mcg intranasally, with sleep-focused community use commonly describing evening dosing 1-2 hours before bed.
Best for: users primarily on a GH-optimization or recovery protocol who want sleep deepening as a secondary benefit, or those who can't tolerate MK-677's metabolic side effects.
Ipamorelin is described in published research as the first selective growth hormone secretagogue — releasing GH without significantly affecting ACTH or cortisol, even at doses over 200-fold higher than its effective GH-releasing dose. This selectivity is its primary differentiator from MK-677 for sleep applications.
The sleep rationale is indirect but mechanistically grounded. Published research describes GH-deficient adults as having measurably decreased deep sleep, with GH replacement partially restoring slow-wave sleep duration. The relationship is bidirectional: slow-wave sleep promotes GH release, and GH signaling supports slow-wave sleep. By selectively amplifying the evening GH pulse without cortisol elevation, ipamorelin theoretically reinforces this feedback loop.
Compared to MK-677, ipamorelin has a different risk-benefit profile. MK-677 has direct trial evidence for stage IV and REM improvement; ipamorelin's sleep benefits are inferred from the GH-slow-wave-sleep relationship rather than directly demonstrated in sleep-endpoint trials. However, ipamorelin does not increase appetite, raise blood glucose, or elevate cortisol — making it cleaner for users with metabolic concerns.
Community reports on ipamorelin cluster around two themes: subtle sleep improvements layered on a broader GH-optimization or recovery protocol (commonly described as easier to wake refreshed rather than dramatic deepening), and the absence of metabolic side effects that some users found dose-limiting on MK-677. Community usage as a standalone sleep intervention is rare; the more frequently described pattern is pairing ipamorelin with CJC-1295 (no DAC) for synergistic GH release, with sleep deepening as a secondary signal of the GH protocol working. Trial protocols and community sources commonly describe 100-300 mcg subcutaneously 30-60 minutes before bed.
Trial-evidence patterns and community usage map cleanly onto reader profiles. Here's how the picks above tend to break down across common audiences:
Users who can't fall asleep due to anxiety or racing thoughts commonly choose selank first. The anxiolytic mechanism targets the hyperarousal circuit that prevents sleep onset, with sleep improvements as a downstream effect.
Users who fall asleep fine but wake unrefreshed (poor deep sleep) commonly choose DSIP. The architecture-targeted mechanism is the most direct match, and community sources commonly describe evaluating after a full 10-day cycle rather than after one or two doses.
Users with age-related sleep decline plus body composition or recovery goals commonly choose MK-677. The strongest single-trial sleep dataset on this list, with oral convenience, makes it a frequently described pick for adults 40+. Community sources commonly describe pivoting to ipamorelin if MK-677's metabolic side effects are unacceptable.
Users on a GH-optimization protocol who want sleep as a secondary benefit commonly choose ipamorelin (often paired with CJC-1295). Cleaner GH release without cortisol elevation or appetite stimulation.
Users avoiding injections entirely are limited to MK-677 (oral) and selank (intranasal). The two non-injection options on this list, each addressing different sleep mechanisms.
Users with both anxiety-driven onset difficulty and poor deep-sleep quality commonly choose the DSIP + selank stack. Each peptide targets a different mechanism — the most commonly described sleep-stacking pattern in community sources.
Users with metabolic concerns (insulin resistance, prediabetes, family history of T2D) commonly avoid MK-677 and choose ipamorelin or DSIP instead. Trial data describe MK-677 raising fasting glucose and insulin even in healthy subjects.
For users tracking sleep alongside broader recovery and body composition goals, ipamorelin appears in multiple categories — see best peptides for muscle growth for the GH-axis-focused ranking.
What Trial and Community Data Describe as Signals of Effect
Three signals appear consistently in published research and community sources, in this order:
Days 1-7: Subjective sleep quality first. This is the most consistently community-reported early signal. DSIP users commonly describe deeper-feeling sleep within the first 1-3 doses; MK-677 trial data describe stage IV and REM changes appearing within the first 7 days; selank's anxiolytic effects are commonly described within days. Absence of any subjective shift by day 7 is what community sources commonly flag as a signal of under-dosing or product-quality issues.
Weeks 2-8: Bloodwork. For MK-677 and ipamorelin, IGF-1 at baseline and 6-8 weeks is the most-tracked downstream marker — trial data describe IGF-1 reflecting integrated GH exposure over days to weeks (more reliable than a single GH draw). Trial data also describe MK-677 raising fasting glucose and insulin, which is why fasting glucose and HbA1c at 8-week intervals show up consistently in community-described monitoring. For DSIP and selank users, morning cortisol and the cortisol awakening response (CAR) provide HPA-axis context.
Weeks 4-12: Subjective restoration. This is when the bloodwork and architecture signals translate to feeling restored on waking. Trial subjects and community sources commonly describe improved between-session recovery, less daytime fatigue, and better cognitive performance over this window. The most commonly described community caveat is that subjective sleep quality plateaus around week 4-6 — if it reverses despite continued use, community sources commonly describe a formal sleep study (polysomnography) as worth considering to rule out obstructive sleep apnea or periodic limb movement disorder, conditions peptides cannot address.
Running sleep peptides without bloodwork is functionally running them blind. The trial-and-community standard is baseline IGF-1 plus a 6-8 week recheck (for GH-class compounds), morning cortisol or CAR for DSIP and selank users, and a CMP and CBC at baseline and quarterly during extended protocols. For users on MK-677 specifically, fasting glucose and HbA1c at 8-week intervals are what community sources commonly describe as non-negotiable.
Schoenenberger GA, Monnier M. Characterization of a delta-electroencephalogram (-sleep)-inducing peptide. Proc Natl Acad Sci USA. 1977;74(3):1282-1286.
Schneider-Helmert D. Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study. Neuropsychobiology. 1987;17(1-2):5-13.
Schneider-Helmert D. Effects of delta-sleep-inducing peptide on 24-hour sleep-wake behaviour in severe chronic insomnia. Eur Neurol. 1987;27(2):120-129.
Zozulia AA, et al. The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity. Bull Exp Biol Med. 2001;131(4):315-317.
